| Literature DB >> 34553093 |
Vibha Mehta1, Jagdish Chander1, Neelam Gulati1, Nidhi Singla1, Hena Vasdeva2, Raman Sardana2, Awadhesh Kumar Pandey3.
Abstract
BACKGROUND ANDEntities:
Keywords: Antifungal susceptibility; Invasive trichosporonosis; Minimum inhibitory concentration; Voriconazole; Trichosporon
Year: 2021 PMID: 34553093 PMCID: PMC8443878 DOI: 10.18502/cmm.7.1.6179
Source DB: PubMed Journal: Curr Med Mycol ISSN: 2423-3420
Figure 1Colony morphology on Sabouraud dextrose agar (SDA) after 48 h of incubation at 37ºC of Trichosporon asahii (a, b):
Dry and highly wrinkled colony morphology of Trichosporon ovoides on SDA (c, d):
Mucoid and shiny colony morphology of Trichosporon mucoides on SDA (e, f):
Risk factors associated with Trichosporonosis
| Risk factor | Trichosporonosis | Invasive Trichosporonosis | Superficial Trichosporonosis | |||
|---|---|---|---|---|---|---|
| Number |
| Number |
| Number |
| |
| Neutropenia | 7 | >0.05 | 7 | >0.05 | 0 | >0.05 |
| Malignancy | 6 | >0.05 | 6 | <0.05 | 0 | >0.05 |
| Intra- venous catheters | 34 | <0.05 | 34 | >0.05 | 0 | >0.05 |
| Urinary catheters | 22 | >0.05 | 22 | <0.05 | 0 | >0.05 |
| Central venous catheters | 6 | >0.05 | 6 | >0.05 | 0 | >0.05 |
| Immunosuppressant intake | 5 | >0.05 | 5 | <0.05 | 0 | >0.05 |
| Steroid intake | 13 | >0.05 | 13 | >0.05 | 0 | >0.05 |
| Surgery | 3 | >0.05 | 3 | <0.05 | 0 | >0.05 |
| Dialysis | 5 | >0.05 | 5 | >0.05 | 0 | >0.05 |
| Intensive care unit stay | 17 | >0.05 | 17 | <0.05 | 0 | >0.05 |
| Antifungal intake | 9 | <0.05 | 5 | >0.05 | 4 | <0.05 |
| Antibiotics intake | 35 | <0.05 | 35 | <0.05 | 0 | >0.05 |
| History of diabetes mellitus | 17 | >0.05 | 16 | >0.05 | 1 | >0.05 |
| Bronchial asthma with chronic obstructive pulmonary disease | 6 | >0.05 | 6 | <0.05 | 0 | >0.05 |
| History of tuberculosis | 2 | >0.05 | 2 | >0.05 | 0 | >0.05 |
Minimum inhibitory concentration of various Trichosporon isolates
| Antifungal agent |
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|
| Amphotericin-B (µg/ml) | MIC range | 0.25-≥16 | 0.25-≥16 | 0.25-≥16 | 0.5-≥16 | 8-≥16 | ≥16 |
| MIC50 | 16 | 16 | 16 | 16 | |||
| MIC90 | 16 | 16 | 16 | 16 | |||
| G mean | 6.964 | 6.964 | 6.964 | 4.832 | 13.125 | ||
| 5-Flucytosine (µg/ml) | MIC range | 0.125-≥64 | 0.125-≥64 | 0.125-≥64 | 0.125-≥64 | 0.125-2 | ≥64 |
| MIC50 | 2 | 2 | 4 | 2 | |||
| MIC90 | 8 | 8 | 16 | 4 | |||
| G mean | 2.234 | 2.234 | 2.234 | 2.858 | 1.811 | ||
| Fluconazole (µg/ml) | MIC Range | ≤0.125-32 | ≤0.125-32 | ≤0.125-32 | ≤0.125-4 | ≤0.125-4 | ≤0.125 |
| MIC50 | 4 | 4 | 4 | 4 | |||
| MIC90 | 8 | 8 | 32 | 4 | |||
| G mean | 2.567 | 2.567 | 2.567 | 3.108 | 1.486 | ||
| Itraconazole (µg/ml) | MIC range | ≤0.0313-0.25 | 0.125-0.25 | ≤0.0313-0.25 | ≤0.0313-≤0.0313 | ≤0.0313-≤0.0313 | ≤0.0313 |
| MIC50 | 0.0313 | 0.0313 | 0.0313 | 0.0313 | |||
| MIC90 | 0.0625 | 0.125 | 0.125 | 0.0313 | |||
| G mean | 0.041 | 0.041 | 0.041 | 0.046 | 0.0313 | ||
| Voriconazole (µg/ml) | MIC range | ≤0.0313-0.5 | ≤0.0313-0.5 | ≤0.0313-0.5 | ≤0.0313-0.0625 | ≤0.0313-≤0.0313 | ≤0.0313 |
| MIC50 | 0.0313 | 0.0313 | 0.0313 | 0.0313 | |||
| MIC90 | 0.0625 | 0.25 | 0.125 | 0.0313 | |||
| g mean | 0.038 | 0.038 | 0.038 | 0.043 | 0.0313 | ||
| Posaconazole (µg/ml) | MIC range | ≤0.0313-2 | ≤0.0313-2 | ≤0.0313-2 | ≤0.0313-0.5 | ≤0.0313-≤0.0313 | ≤0.0313 |
| MIC50 | 0.125 | 0.125 | 0.125 | 0.125 | |||
| MIC90 | 0.5 | 0.5 | 1 | 0.25 | |||
| G mean | 0.128 | 0.128 | 0.128 | 0.164 | 0.093 | ||
| Caspofungin (µg/ml) | MIC Range | ≤0.125-16 | ≤0.125-16 | ≤0.125-16 | ≤0.125-8 | ≤0.0125-4 | ≤0.125 |
| MIC50 | 8 | 8 | 8 | 4 | |||
| MIC90 | 8 | 8 | 8 | 8 | |||
| G mean | 3.531 | 3.531 | 3.531 | 4.443 | 2.438 |
MIC: Minimum inhibitory concentration, G mean: geometric mean